Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Alzheimer's Disease
Interventions: Rosi XR, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: PH-797804, Moxifloxacin, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urinary Tract Infection
Interventions: Cefpodoxime, Ciprofloxacin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Seattle, Washington

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetic Foot Ulcers
Interventions: Gentamicin Topical Gel, Ciprofloxacin, Doxycycline; Drug
Lead sponsor: Royer Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Miami, Florida • Miami Lakes, Florida + 4 more

Conditions: Infection
Interventions: Ciprofloxacin, trimethoprim-sulfamethoxazole, cefuroxime, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 90 Years · Male only
Enrollment: 563 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Saline, PF-02545920, Ketamine, Placebo; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Cataract Extraction
Interventions: Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Rockville Centre, New York

Conditions: Influenza, Human
Interventions: 600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Neisseria Gonorrhoeae Infection
Interventions: Ciprofloxacin 500 mg; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Autistic Disorder
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Conjunctivitis
Interventions: moxifloxacin, polytrim; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 1 Year to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
Interventions: Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician); Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 26
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more

Conditions: Schizophrenia
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Downy, California • Glendale, California • Miami, Florida + 5 more

Conditions: Cocaine Abuse
Interventions: Aripiprazole + Cocaine, Placebo + Cocaine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Complicated Urinary Tract Infection, Pyelonephritis
Interventions: CXA-201, Levofloxacin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: San Diego, California • Wheat Ridge, Colorado • Hialeah, Florida + 2 more

Conditions: Community-Acquired Bacterial Pneumonia (CABP)
Interventions: JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label); Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more

Conditions: Bacterial Conjunctivitis
Interventions: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Month and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Bacterial Conjunctivitis
Interventions: quinolone; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Month and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania

Conditions: HIV Infections
Interventions: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bacterial Pneumonia, Community-Acquired Infections
Interventions: Omadacycline, Moxifloxacin; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more

Conditions: Sarcoidosis; Antimycobacterial Therapy
Interventions: Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 6
States / cities: Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more

Search by objective public record fields.

QTc Study of Rosi XR in Healthy Volunteers

A Study to Investigate the Effect of PH-797804 on QTc Interval

Cefpodoxime vs Ciprofloxacin for Acute Cystitis

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

Moxifloxacin vs. Polytrim for Conjunctivitis

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Effects of Aripiprazole on Cocaine Craving and Self-Administration

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

AL-15469A for the Treatment of Bacterial Conjunctivitis

AL-15469A for the Treatment of Bacterial Conjunctivitis

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis